ProBioGen AG has signed a commercial license agreement with Roche for applying ProBioGen’s proprietary GlymaxX technology to boost the antibody’s ADCC anti-tumor activity.   The GlymaxX technology for production of afucosylated proteins is universally applicable, simple and potent. The advantage of the GlymaxX technology is that a single GlymaxX modified cell line is sufficient to produce both, completely fucosylated or afucosylated antibodies and those with an intermediate defined fuscosylation...